Key result
Fondaparinux linked to ~70% less bleeding and fewer ischemic events vs enoxaparin in NSTE-ACS.
Why the study?
The optimal anticoagulation choice between fondaparinux and enoxaparin in NSTE-ACS remains debated, particularly regarding bleeding and ischemic outcomes.
Does fondaparinux reduce composite ischemic events and bleeding complications compared to enoxaparin in patients with NSTE-ACS?
Does fondaparinux reduce composite ischemic events and bleeding complications compared to enoxaparin in patients with NSTE-ACS?
In a real-world, resource-constrained setting, fondaparinux demonstrated superior safety and effectiveness over enoxaparin by significantly reducing bleeding complications and composite ischemic events in NSTE-ACS patients.
Answers are grounded in this paper and cite their sources.
Fondaparinux was associated with fewer events in this observational NSTE-ACS cohort; supports consensus but leaves open randomized confirmation before practice change.
Background Non-ST-elevation acute coronary syndrome (NSTE-ACS) remains a major contributor to morbidity and mortality worldwide. Optimal anticoagulation is critical for preventing complications, but the choice between fondaparinux and enoxaparin remains debated, particularly regarding bleeding and ischemic outcomes. The objective of this study was to compare the safety profile, bleeding complications, ischemic outcomes, mortality, and composite adverse events between fondaparinux and enoxaparin in NSTE-ACS patients in Bangladesh. Methods This prospective observational study enrolled 177 NSTE-ACS patients from Noakhali Medical College and Hospital, Bangladesh, between January and December 2022. Patients received either fondaparinux (n=87) or enoxaparin (n=90). Bleeding and ischemic events, mortality, and composite outcomes were assessed at baseline, 3-month, and 6-month follow-ups. Multivariable logistic regression was performed to evaluate predictors of composite outcomes. Results Total bleeding incidence was significantly lower in fondaparinux-treated patients (6.90% vs. 23.33%, p=0.002), notably during index hospitalization (4.60% vs. 17.78%, p=0.006). Fondaparinux significantly reduced myocardial infarction (3.45% vs. 14.44%, p=0.016), recurrent ischemia (11.49% vs. 24.44%, p=0.025), and hospitalization due to heart failure (4.60% vs. 14.44%, p=0.026). Mortality was lower with fondaparinux but not statistically significant (13.79% vs. 25.56%, p=0.050). The composite endpoint of mortality and ischemic events was significantly lower in fondaparinux-treated patients (20.69% vs. 40.00%, p=0.005). Multivariable analysis revealed fondaparinux as an independent protective factor against composite outcomes (OR=0.336, 95% CI: 0.166-0.683, p=0.003), with no significant predictive value found for age, sex, hypertension, diabetes, smoking, or time to intervention. Conclusions Fondaparinux demonstrates superior safety and effectiveness over enoxaparin in reducing bleeding complications and ischemic events among NSTE-ACS patients. These findings support its preferential use in resource-constrained clinical settings.
No takes yet. Share an insight, caveat, or question.
Rahman et al. (2025) studied this question. Fondaparinux reduced total bleeding incidence to 6.90% and ischemic events compared to enoxaparin's 23.33% and 14.44%, respectively, in NSTE-ACS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: